anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
2.1 Dosing Information    
Tizanidine Tablets, USP tablets may be prescribed with or without food. Once the formulation has been selected and the decision to take with or without food has been made, this regimen should not be altered.

Food has complex effects on tizanidine pharmacokinetics, which differ with the different formulations. Tizanidine Capsules and Tizanidine Tablets, USP are bioequivalent to each other under fasting conditions (more than 3 hours after a meal), but not under fed conditions (within 30 minutes of a meal). These pharmacokinetic differences may result in clinically significant differences when switching administration of tablet and capsules and when switching administration between the fed or fasted state. These changes may result in increased adverse events, or delayed or more rapid onset of activity, depending upon the nature of the switch. For this reason, the prescriber should be thoroughly familiar with the changes in kinetics associated with these different conditions [see Clinical Pharmacology (12.3)].

The recommended starting dose is 2 mg. Because the effect of Tizanidine Tablets, USP peaks at approximately 1 to 2 hours post-dose and dissipates between 3 to 6 hours post-dose, treatment can be repeated at 6 to 8 hour intervals, as needed, to a maximum of three doses in 24 hours.

Dosage can be gradually increased by 2 mg to 4 mg at each dose, with 1 to 4 days between dosage increases, until a satisfactory reduction of muscle tone is achieved. The total daily dose should not exceed 36 mg. Single doses greater than 16 mg have not been studied.

2.2 Dosing in Patients with Renal Impairment 

Tizanidine Tablets, USP should be used with caution in patients with renal insufficiency (creatinine clearance < 25 mL/min), as clearance is reduced by more than 50%. In these patients, during titration, the individual doses should be reduced. If higher doses are required, individual doses rather than dosing frequency should be increased [see Warnings and Precautions (Error! Hyperlink reference not valid.)].

2.3 Dosing in Patients with Hepatic Impairment 

Tizanidine Tablets, USP should be used with caution in patients with any hepatic impairment. In these patients, during titration, the individual doses should be reduced. If higher doses are required, individual doses rather than dosing frequency should be increased. Monitoring of aminotransferase levels is recommended for baseline and 1 month after maximum dose is achieved, or if hepatic injury is suspected. [see Use in Specific Populations (8.7)]

2.4 Drug Discontinuation 

If therapy needs to be discontinued, particularly in patients who have been receiving high doses (20 mg to 36 mg daily) for long periods (9 weeks or more) or who may be on concomitant treatment with narcotics, the dose should be decreased slowly (2 mg to 4 mg per day) to minimize the risk of withdrawal and rebound hypertension, tachycardia, and hypertonia [see Drug Abuse and Dependence (9.3)].
A group of participants will undergo 1x1 transcranial direct current stimulation of the temporal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left structures using 4x1 stimulation (e.g., 1mA left temporal, 1mA right temporal, sham; 2mA left temporal, 2mA right temporal, sham).
PURPOSE: To provide pancreatin micropellet particles which are coatable with gastric juice resistant films and may be packed into capsules at a high active substance content into capsules due to a higher bulk density and a preparation thereof. CONSTITUTION: The pancreatin micropellet particles coatable with the gastric juice resistant films contain 65 to 85 wt.% pancreatin, have a bulk density of 0.6 to 0.85 g/ml and consist of the pancreatin, polyethylene glycol (PE) 4000 and dilute paraffin soln. The ratios thereof are 15 to 50 pts.(wt.), more particularly 20 to 30 pts. polyethylene glycol and 1.5 to 5 pts. and more particularly 2 to 3 pts. dilute paraffin soln. per 100 pts. pancreatin. The particles have the form of spheres or ellipsoids having a spherical diameter or minor axis in a range of 0.7 to 1.4 mm, more particularly 0.8 to 1.2 mm and have a grain size distribution in which at least 80% of the particles exhibits the ratio of the minor axis and major axis within a range of 1:1 to 1:2.
Laparoscopic total mesorectal excision is the main surgical approach for treating rectal cancer, but there is still no clear consensus on the issue of low ligation of the inferior mesenteric artery during the procedure. Robotic surgery has been shown to have certain advantages over laparoscopic surgery in multiple studies, but further research is needed to better understand the outcomes of robotic surgery in the context of low ligation procedures. In this study, we included 1590 patients with mid-low rectal cancer. Among them, 942 patients underwent low ligation surgery (LL), divided into 138 in the robotic group and 804 in the laparoscopic group. The high ligation surgery (HL) group consisted of 648 patients. The results of LL vs HL showed that the LL group had faster bowel movement recovery (P = 0.003), lower anastomotic leak rate (P = 0.032), and lower International Prostate Symptom Score (IPSS) at 6 months postoperatively (P < 0.001). The results of Rob-LL vs Lap-LL showed that the Rob-LL group had longer operative time (P < 0.001), less blood loss (P = 0.001), more lymph nodes retrieved (P = 0.045), and lower Wexner score at 2 weeks postoperatively (P = 0.029). The concept of low ligation of the inferior mesenteric artery is a promising surgical approach that can accelerate the patient's functional recovery. When combined with robotic technology, it may offer more benefits than laparoscopic techniques.
Within the current obesogenic environment, the prevalence of overweight and obesity has dramatically increased over the past 40 years. As a result, approximately 40% of Americans attest to being on a diet, with most of these efforts being unsuccessful. Most weight loss diets rely on self-control and reflective thinking (e.g., making conscious food choices multiple times per day), despite the fact that responses to appetitive foods often occur through implicit (unconscious) processes. The proposed study is a randomized clinical trial for weight loss that targets these implicit processes through the use of a computerized, food-specific, go/no-go task. This task has previously resulted in reduced food consumption in laboratory settings, and small but significant weight loss in two brief intervention studies. The purpose of this study is to replicate one prior study and to compare different doses of the intervention. Participants will be assigned to one of three groups: high intensity, low intensity, or active control, and will be assessed on a number of variables pre- and post-intervention. Changes in body weight, food evaluation, frequency of self-reported food consumption, and eating disinhibition scores will be evaluated. It is hypothesized that individuals receiving the food-specific go/no-go training (high intensity and low intensity groups) will experience greater weight loss, decreased disinhibition with food, and reduced snacking of the targeted foods than those in the active control group. It is also hypothesized that the high intensity intervention will be more effective than the low intensity intervention across these variables. Moderators (e.g., dietary restraint, disinhibition) will also be explored throughout this study, along with the mechanism of devaluation of specific foods.
The invention discloses an oral sustained-release Anemone flaccida Fr. Schmidt saponin W3 capsule and a preparation method thereof. The oral sustained-release Anemone flaccida Fr. Schmidt saponin W3 capsule comprises Anemone flaccida Fr. Schmidt saponin W3, polyvinylpyrrolidone, Eudragit and other common auxiliary materials. The preparation method comprises the following steps of preparing a drug-containing coating liquid, carrying out coating to form a drug-containing sustained-release film, preparing a sustained-release coating liquid arranged outside a drug layer, carrying out coating to form a sustained-release film outside the drug layer, preparing sustained-release pills and carrying out capsule loading. After oral administration, the oral sustained-release Anemone flaccida Fr. Schmidt saponin W3 capsule can realize lasting and stable plasma concentration.
Atrial fibrillation (AF) is globally the most common arrhythmia associated with significant morbidity and mortality. It impairs the quality of the patient's life, imposing a remarkable burden on public health, and the healthcare budget. The detection of AF is important in the decision to initiate anticoagulation therapy to prevent thromboembolic events. Nonetheless, AF detection is still a major clinical challenge as AF is often paroxysmal and asymptomatic. AF screening recommendations include opportunistic or systematic screening in patients ≥65 years of age or in those individuals with other characteristics pointing to an increased risk of stroke. The popularities of well-being and taking personal responsibility for one's own health are reflected in the continuous development and growth of mobile health technologies. These novel mobile health technologies could provide a cost-effective solution for AF screening and an additional opportunity to detect AF, particularly its paroxysmal and asymptomatic forms.
PURPOSE:To obtain the title emulsified composition having the wide range of use as various cosmetics by adding sugar fatty acid ester, enzyme treated lecithin or hydrogenated enzyme treated lecithin and lower alcohol and/or silicone. CONSTITUTION:Sugar fatty acid ester, enzyme treated lecithin or hydrogenated enzyme treated lecithin and lower alcohol and/or silicone are contained to prepare an oil in polyhydric alcohol (having two or more hydroxyl groups) type emulsified composition. The compositional ratio of polyhydric alcohol is pref. about 5-60wt.%. As sugar fatty acid ester, a compound having a degree of substitution of sugar ester of 18 or less composed of 12-18C saturated or unsaturated fatty acid is designated. Enzyme treated lecithin or hydrogenated enzyme treated lecithin is pref. added in an amount of about 0.05-5.0%. As lower alchol, ethanol or isopropanol is designated.
Effective postoperative pain management is essential to the patient's recovery. The use of opioids as the primary line of pain treatment has been known to increase rates of length of stay, pulmonary complications, paralytic ileus, and nausea and vomiting. Therefore, guidelines strongly recommend alternative paths to reduce opioid consumption through multimodal analgesia, and the transversus abdominis plane block(USG-TAP) has been considered to be one of these optimistic alternatives. A comprehensive systematic search was conducted in four databases until April 2024. We only considered for this analysis randomized controlled trials that assessed the USG-TAP as part of multimodal anesthesia in patients undergoing laparoscopic bariatric surgery. Eleven studies comprising 789 patients were included in the meta-analysis. Our results showed a significant decrease in opioid consumption after the first 24 h of surgery (MD - 32.02 mg; 95% IC - 51.33, - 12.71; p < 0.01) and fewer patients required extra-dose of opioid (OR 0.20; 95% IC 0.07, 0.62; p < 0.01). The pain score showed to be also improved with the TAP block (MD - 0.69; 95% IC - 1.32, - 0.07; p = 0.03). No difference concerning time to deambulate, nausea and vomiting, and time of surgery was observed among the studies. This study reinforces the benefits of the use of USG-TAP block as part of multimodal analgesia in patients undergoing laparoscopic bariatric surgery.
Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
Intervention arm: Patients in the Ultraviolet B lamp group will continue vitamin D2/D3 daily and will receive 3 treatment sessions of Ultraviolet B light once a week for 12 weeks. Patients will receive Ultraviolet B light from Ultraviolet B lamp at a distance of 14 inches for duration of 5 minutes each area while wearing an Ultraviolet eye shield. Areas of skin exposure will include 3 different areas amounting to 27% of body surface area. 9% body surface area will include front of abdomen, lower back, each arm, each leg is 18%, each thigh. Ultraviolet B light sessions will be supervised and conducted by study personnel or Center for Clinical and Translational Research staff. A food questionnaire will be reviewed at each visit to assess dietary intake of calcium. Skin exam will be conducted at the beginning and end of the session.
Patients receive nivolumab IV over 60 minutes once every 2 weeks. Treatment repeats every 2 weeks for 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy at screening, months 3, 6, and 12, as clinically indicated, and during off-study evaluation. Patients also undergo collection of blood samples at screening, weeks 9, 13, 25, and 53, and during off-study evaluation or at time of clinically suspected relapse. Patients may undergo ECHO as clinically indicated.
Atrial fibrillation (AF) and heart failure (HF) are common cardiovascular conditions that frequently coexist. Among patients with HF, more than one-half also have AF. Both are associated with significant morbidity and mortality. Moreover, the prevalence of each is increasing globally, and this trend is expected to continue owing to an aging population and increased life expectancy. Diagnosis of AF in a patient with HF is associated with greater symptom burden, more frequent hospitalizations, and a worse prognosis. Guideline-directed medical therapy (GDMT) for HF can affect the incidence of AF. Once present, AF can influence the efficacy of some components of GDMT for HF. In this review, we discuss the effect of GDMT for HF across the spectrum of ejection fraction on prevention of AF as well as the benefit of GDMT in patients with vs without AF.
IFN preparations wherein IFN is modified so as to elevate the stability of IFN and allow the exhibition of the IFN drug effect at a target site. Such an interferon-polymer complex can be obtained by mixing interferon with a polymer having spermine transferred thereinto in the presence of a metal ion. As the interferon, β-interferon is favorable. As the polymer, use is made of pharmaceutically acceptable polymers such as water-soluble polysaccharides and polyhydric alcohol polymers. As the polysaccharides, dextran and pullulan are favorable. As the polyhydric alcohol polymers, polyalkylene glycols and polyvinyl alcohol are favorable.
The present invention relates to toothpaste including graviola as a main ingredient, and to a method for producing the same. Graviola is a tropical plant, and according to the results of analyses on components, leaves, stems, and fruit extracts thereof include 82.8 g of moisture per 100 g, and contain 1.00 g of protein, 0.97 g of fat, 14.63 g of carbohydrate, 0.79 g of fiber, 60 g of minerals, 10.3 mg of calcium, 27.7 mg of phosphorus, 0.64 mg of iron, 0.11 mg of thiamine, 0.05 mg of riboflavin (vitamin B2), 1.28 mg of niacin, 29.6 mg of ascorbic acid, 11 mg of tryptophan, 7 mg of methionine, and 60 mg of lysine. A pure seed of graviola contains 2.4 g of protein, 20.5 g of ether (alcohol), 55.1 g of carbohydrate, 8.0 g of edible fiber, 357.1 mg of potassium, 17.4 mg of sodium, 149 mg of calcium, 136 mg of phosphorous, and 12.6 mg of magnesium. (Analyses made at the Laboratorio FIM de Nutricion, Havana, Cuba.) Such components include factors for preventing skin diseases such as dermatitis and inhibiting inflammation. The present invention relates to a toothpaste composition including such graviola as a main ingredient, and maximizing oral health by having added plant extracts which harmonize well with the effective properties of graviola.
The present invention pertains to a compound represented by formula (1a) [in the formula: p represents 1 or 2; R1 to R4 represent a hydrogen atom, etc.; ring A represents a cycloalkylene, etc.; L represents a single bond, etc.; and R represents methyl, etc.] or a pharmaceutically acceptable salt thereof. This compound exerts an anticancer effect by inhibiting the binding of an MLL fusion protein fused with a typical fusion partner gene inducing MLL leukemia, for example AF4 or AF9, to menin.
INTRODUCTION: Recent data question the use of aspirin as a bedrock of antiplatelet therapy in patients with arterial diseases. There are controversies regarding the efficacy of aspirin therapy with respect to specific demographic characteristics, dose and formulations, benefit in primary prevention, and duration in secondary prevention. Importantly, to balance the ischemic benefits and the risk of excessive bleeding following a coronary event, recent studies have investigated strategies to discontinue aspirin therapy and continue with P2Y12 receptor inhibitor monotherapy. However, the precise time when to discontinue aspirin is still unresolved.
AREAS COVERED: Evidence from recent studies evaluating the role of aspirin in primary and secondary prevention studies was collected from a selective literature search. In this review, the authors discuss current recommendations, large-scale studies of aspirin therapy, controversies, and potential future opportunities for aspirin therapy.
EXPERT OPINION: With the new evidence showing lower bleeding risk with aspirin-free strategies in both primary and secondary prevention studies, the role of aspirin is being revaluated with P2Y12 receptor inhibitor monotherapy. The potential benefits of novel aspirin formulations and alternative delivery methods, such as inhaled aspirin, are undergoing much-needed investigation with the goal of optimizing care for a wide range of patients.
Will receive a 100ml infusion of 0.9% Sodium Chloride (placebo) over 30mins. Participants will receive infusions at 2 time-points, the first prior to surgery, and the second 20-28 hours later. At each infusion, the placebo will be followed by a further 100ml infusion of 0.9% Sodium Chloride over 15mins.
PROBLEM TO BE SOLVED: To provide a technique enabling a proteinic medicinal agent such as interferon-β to be effectively appilied to intraocular diseases such as of corpus vitreum and retina. SOLUTION: This technique is in the form of a composition which is obtained by adsorbing a proteinic medicinal agent (e.g. an interferon. esp. interferon-β) to the surface of fine particles (<1000nm, pref. 50-500nm in average size) consisting of a lactic acid copolymer composed pref. of lactic acid unit and glycolic acid unit, or a scleral plug molded from the composition.
The present invention provides gel and a tooth socket for treating tooth sensitivity. The gel is composed of Chinese medicinal components by a special technology; the gel has no toxic or side effect. The tooth socket with a medicine storing bag is made of soft resin elastic materials; the tooth socket is put in the oral cavity; medicines stored in the medicine storing bag can effectively and exactly act on the teeth needing treating for a long time. The other positions of the tooth socket are tightly attached to other positions of the oral cavity, which makes the medicines isolate with the outside. The medicines are free from external influence and are incapable of resulting in harm and discomfort to the oral cavity. The gel is used as a tooth desensitizer and conforms to the standard of the ideal desensitizer; by using the tooth socket, the gel has the advantages of safe operation, reliability, convenience and outstanding effect.
Patients receive obinutuzumab IV over 3-4 hours on days 1, 2, 8, and 15 of course 1 and day 1 of courses 2-6 and lenalidomide PO QD on days 9-28 of course 1 and days 1-28 of all subsequent courses. Treatment with obinutuzumab repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive lenalidomide PO QD in the absence of disease progression or unacceptable toxicity.
PCT No. PCT/JP95/00489 Sec. 371 Date Sep. 13, 1996 Sec. 102(e) Date Sep. 13, 1996 PCT Filed Mar. 17, 1995 PCT Pub. No. WO95/25752 PCT Pub. Date Sep. 28, 1995An amphoteric porous particulate containing a basic polysaccharide and a polymer of an organic acid containing a reactive vinyl group or a salt thereof and having an average particle size of 50  mu m or less, is capable of adsorbing a large amount of an acid or a base that is stronger than the acid or basic groups thereof and is useful in a deodorant or a cosmetic. The amphoteric porous particulate is made by emulsifying or suspending an aqueous solution containing a basic polysaccharide and an organic acid having a reactive vinyl group in a hydrophobic solvent, followed by polymerization. A deodorant may be made of a chitosan particulate having an average particle size of 0.01 to 50  mu m. A polysiloxane having long-chain alkyl groups and a melting point of 20 DEG  C. or above is useful as an oil component of a deodorant.
Low-Level Laser Therapy was applied in the test group with a Diode Laser Fox (A.R.C. Laser, Italy) using these parameters: a wavelength of 810 nm, a power of 0.6 W, a power density of 1.2 W/cm2, a beam area of 0.08 cm2 and an energy of 6 J with an application time per point of 10 seconds in 56 points (3 in the vestibular mucosa of the 4 quadrants, 6 in each of the two buccal mucosa, 6 in the hard palate, 4 in each lateral of the tongue, 6 in the dorsum of the tongue and 4 sublingual points) with a distance between points of 2mm. It was applied, therefore, a dose of 12 J/cm2 in a continuous mode in a total of 10 sessions, 2 sessions per week for 5 weeks.
The utility of soybeans having a composition of greater than 40% of the protein as beta-conglycinin and less than 10% of the protein as glycinin for making highly functional high beta-conglycinin compositions was discovered. The discovered ingredients are useful for mimicking the texturizing properties of casein while also maintaining or improving physiological benefits of soy protein ingredients (e.g., cholesterol and triglyceride lowering properties). The high stability of the high beta-conglycinin compositions against protein-protein aggregation reactions is valuable for creating good tasting beverages and beverage mixes. Cheese with good spreadability, gloss and smoothness was made using an enzyme-modified version of the new ingredient composition. Cheese with good firmness and meltability was also created using a different enzyme-treatment High beta-conglycinin compositions were found to demonstrate excellent emulsifying and gelling properties in the pH region (5.5-6.2) relevant to meet applications. High beta-conglycinin compositions also have possible use for improving the composition of essential amino acids for infant humans and animals.